This category if for the News items that RapAdmin identifies for the home page of the site. Please don’t use this category for posts.
","posters":[{"extras":"latest single","description":"Original Poster, Most Recent Poster","user_id":1,"primary_group_id":null,"flair_group_id":null}]},{"id":23676,"title":"How the Collapse of Nitric Oxide Signaling Accelerates Aging","fancy_title":"How the Collapse of Nitric Oxide Signaling Accelerates Aging","slug":"how-the-collapse-of-nitric-oxide-signaling-accelerates-aging","posts_count":31,"reply_count":16,"highest_post_number":32,"image_url":"https://www.rapamycin.news/uploads/default/original/3X/8/7/874604f5e79d797080000b87198192fd35f56d74.jpeg","created_at":"2026-02-20T21:04:54.246Z","last_posted_at":"2026-07-10T06:30:47.272Z","bumped":true,"bumped_at":"2026-07-10T06:30:47.272Z","archetype":"regular","unseen":false,"pinned":false,"unpinned":null,"visible":true,"closed":false,"archived":false,"bookmarked":null,"liked":null,"tags":[],"tags_descriptions":{},"views":4907,"like_count":63,"has_summary":false,"last_poster_username":"L_H","category_id":5,"pinned_globally":false,"featured_link":null,"news_body":"\nNitric Oxide (NO) is frequently misunderstood as merely a vasodilator or a performance-enhancing supplement. However, this review establishes NO as a foundational “molecular currency” of aging that undergoes a catastrophic devaluation as we get older. The central thesis is that aging is not just a passive decline in NO levels, but an active dysregulation where the machinery meant to produce NO—specifically endothelial Nitric Oxide Synthase (eNOS)—breaks down (“uncouples”) and begins manufacturing damaging free radicals instead.
\nThis physiological switch creates a vicious cycle: as NO bioavailability drops, mitochondrial function falters, vascular stiffness increases, and cognitive decline accelerates. The review painstakingly maps this failure across multiple organ systems, linking the loss of NO signaling to erectile dysfunction, skin aging, renal failure, and neurodegeneration. Crucially, the paper argues that restoring the “coupling” of NO synthase—rather than just blasting the system with arginine—is the key therapeutic target. It highlights a convergence of synthetic drugs (like PDE5 inhibitors) and natural compounds (like resveratrol and icariin) that can reverse this uncoupling, potentially restoring youthful signaling phenotypes.
\nSource:
\nAging is, to some degree, a vascular and mitochondrial disease, heavily mediated by the progressive loss of nitric oxide (NO) bioavailability. NO is a ubiquitous gaseous signaling molecule essential for regulating skeletal muscle blood flow, mitochondrial ATP production, and overall endothelial health. While sedentary aging decimates endogenous NO production—leading to a steady 1% annual decline in VO2max after age 30 and severely impaired functional sympatholysis—lifelong aerobic exercise appears to preserve it. Older “Masters athletes” maintain NO levels comparable to healthy young adults, effectively insulating themselves against primary vascular aging and delaying physiological decline.
\nThe central question is whether exogenous supplementation can reverse age-related NO deficits in the broader population.
\nThe clinical data reveals a sharply split verdict. Interventions targeting the canonical L-arginine/NOS pathway (L-citrulline, L-arginine) or the alternative nitrate-nitrite-NO pathway (inorganic nitrate, beetroot juice) successfully elevate surrogate systemic NO biomarkers in older adults. However, the translation of these biochemical markers into measurable endurance or exercise performance improvements is highly inconsistent. Dietary nitrate shows ergogenic promise primarily in older adults suffering from distinct clinical pathologies, such as chronic obstructive pulmonary disease (COPD) or heart failure. Conversely, performance benefits for healthy or highly trained older cohorts remain largely unproven, with several trials showing null results. Furthermore, dietary antioxidants and (poly)phenols fail to demonstrate reliable efficacy for enhancing NO or performance in this demographic. Consequently, while NO manipulation remains biologically plausible for extending healthspan, current over-the-counter protocols lack the rigorous, healthy-cohort validation required to guarantee functional outcomes in aging individuals.
\nSource:
\nRelated Reading:
\nA single-author meta-analysis from Johns Hopkins pooled 22 rodent lifespan experiments (spanning 27 years, 6 countries, 4 species) on the FDA-approved MAO-B inhibitor L-deprenyl (selegiline). The drug produced a statistically significant, moderate increase in average lifespan (standardized mean difference 0.68, p = 0.0002). Effects were larger at higher doses and when treatment started in older animals. Critically, the benefit was not an artifact of unusually short-lived control animals. However, a re-analysis of the one dog study showed the survival benefit vanished once age at enrollment was accounted for, underscoring that translation to humans remains unproven.
\nL-deprenyl, sold as selegiline, has spent three decades as a bit-player in longevity science: an FDA-approved Parkinson’s and depression drug that a handful of labs kept quietly showing could make old rodents live longer. The problem was that the field never trusted the result. The studies were old, scattered across continents and decades, and geroscience has learned the hard way that “lifespan extension” often evaporates on closer inspection.
\nThis new analysis, published in the high-impact journal Ageing Research Reviews, is the most rigorous attempt yet to settle the question. Michael Bene of Johns Hopkins gathered every credible rodent survival experiment on the drug and ran them through a modern statistical meta-analysis. The verdict: the effect is real, reproducible, and of moderate size. Across mice, rats and hamsters, treated animals reliably out-survived their controls, with an effect size (SMD 0.68) that sits comfortably between the noise of a null result and the strong signals seen with heavyweight interventions like caloric restriction and rapamycin.
\nThe Big Idea is not just “a drug works.” It is that L-deprenyl clears the bars that usually trip up longevity claims. There was no detectable publication bias. And, most importantly, the effect was not driven by the field’s most notorious confounder: sickly, short-lived control animals that make any intervention look good by comparison. When Bene tested for this, he found the opposite pattern - the benefit was, if anything, larger in studies where controls lived longer.
\nTwo findings sharpen the translational angle. Effects grew stronger with higher doses and, strikingly, with older age at treatment onset - hinting that this is a drug you might start late in life rather than in youth. That fits the geroscience dream of a pill for people who are already old.
\nThe cautionary counterweight is the dogs. A 1997 study had reported that L-deprenyl prolonged life in elderly dogs. Bene re-analyzed the raw survival data and found that once you adjust for the fact that treated and untreated dogs entered the study at very different ages, the “benefit” was no longer statistically significant (hazard ratio 0.38, but confidence interval crossing 1.0). The trend still favored the drug, and the study was badly underpowered - but it is a reminder that a robust rodent signal is not a human promise. No human longevity trial has ever been run. This paper makes the strongest case yet that one should be.
\nImpact Evaluation:
\nThe traditional view of the gut as a mere digestive tube is being replaced by a more sophisticated understanding: it is a central “bioreactor” that produces a diverse array of Gut Microbiota-Derived Metabolites (GMDMs) that function as systemic immune signaling molecules. A landmark review published in Ageing Research Reviews (2026) by researchers from the University of Toronto and the Buck Institute for Research on Aging details how the aging process, or “biome-aging,” triggers a fundamental shift in these chemical outputs. This shift is a primary driver of inflammaging —the chronic, low-grade systemic inflammation that underpins nearly all age-related diseases (ARDs).
\nThe “Big Idea” is that youth is characterized by a “eubiotic” state where the gut produces high levels of anti-inflammatory compounds like short-chain fatty acids (SCFAs) and specific tryptophan derivatives. These molecules reinforce the gut barrier and program the immune system toward a state of tolerance and repair. However, as we age, microbial diversity declines, leading to a “dysbiotic” profile. This transition results in the depletion of protective metabolites and the accumulation of pro-inflammatory ones, such as trimethylamine N-oxide (TMAO) and branched-chain amino acids (BCAAs).
\nThe paper highlights the “Gut-Organ Axes,” demonstrating that these metabolites travel through the blood to reprogram the immune niches of the liver, brain, heart, and muscles. For instance, the loss of gut-derived indoles directly accelerates neuroinflammation and cognitive decline, while elevated TMAO promotes vascular stiffening and kidney fibrosis. Critically, the authors argue that this process is bidirectional : a weakening immune system further disrupts the gut environment, creating a self-reinforcing loop of decline.
\nThe review concludes that GMDMs are not just biomarkers of aging but actionable targets. By leveraging AI-driven multi-omics, clinicians may soon be able to prescribe “precision geromedicine”—tailored biotics, fecal transplants, or engineered microbes—to restore a youthful metabolite profile and extend human healthspan.
\nActionable Insights To mitigate biome-aging and suppress inflammaging, the review identifies several practical interventions:
\nDietary Fiber and Prebiotics : High intake of fermentable fibers (inulin, resistant starch) is essential to nourish SCFA-producers like Faecalibacterium prausnitzii , which strengthen the gut barrier and reduce systemic endotoxemia. [Confidence: High]
\nPolyphenol Enrichment : Consuming diets rich in polyphenols (found in berries, nuts, and legumes) allows the microbiota to produce Urolithin A , a metabolite that triggers mitophagy and reduces pro-inflammatory cytokines in aging muscles and joints. [Confidence: Medium]
\nTMAO Management : Reducing the overgrowth of Proteobacteria through probiotic intervention can lower TMAO levels, thereby protecting against vascular senescence and cognitive impairment. [Confidence: High]
\nCircadian Alignment : Implementing time-restricted feeding (TRF) helps restore the diurnal oscillations of GMDMs, which resynchronizes peripheral clocks and improves metabolic resilience. [Confidence: Medium]
\nExercise as a Biotic : Regular endurance and cardiorespiratory exercise increase the abundance of Akkermansia muciniphila , enhancing the production of tolerogenic metabolites that preserve muscle mass and cardiac function. [Confidence: High]
\nContext
\nHidden in a plate of shiitake mushrooms is a molecule that may be quietly keeping your cells alive. Ergothioneine (ET) — a sulfur-rich amino acid first isolated from ergot fungus in 1909 — has spent over a century in relative obscurity. That may be about to change.
\nA sweeping new systematic review published in Ageing Research Reviews synthesizes 20 years of evidence (2005–2025) and makes a forceful case: ET is not merely an antioxidant curiosity but a plausible geroprotector — a compound capable of targeting multiple molecular mechanisms that drive biological aging simultaneously.
\nThe big idea begins with a specialized protein called OCTN1, encoded by the gene SLC22A4. Unlike generic antioxidants that spray-and-pray across tissues, OCTN1 acts as a precision delivery system, ferrying ET specifically into the cells and organs most vulnerable to oxidative damage: the brain, liver, kidneys, eyes, and bone marrow. This selective accumulation is not passive — it is active, energy-dependent, and regulated. Critically, blood levels of ET peak in adolescence at approximately 3.7 mg/100 mL and then decline progressively with age. Lower ET levels have been independently correlated with frailty, mild cognitive impairment, Parkinson’s disease, and all-cause mortality in large cohort studies. This age-related depletion pattern is one reason Nobel laureate biochemist Bruce Ames proposed the “longevity vitamin” hypothesis — the idea that ET is a micronutrient we chronically under-consume, and whose deficit accelerates aging.
\nThe review maps ET’s effects onto the canonical “Hallmarks of Aging” framework. Its actions span telomere preservation (by protecting guanine-rich telomeric DNA from oxidative attack and upregulating SIRT1/SIRT6), mitochondrial quality control (restoring mitophagic flux via PINK1/Parkin pathways), suppression of the pro-inflammatory Senescence-Associated Secretory Phenotype (SASP) via NF-kB inhibition, and modulation of the mTORC1-S6K1 nutrient-sensing axis.
\nBut the most intellectually disruptive finding reviewed here concerns a newly characterized mechanism: ET does not merely neutralize reactive oxygen species — it actively reprograms cellular energy metabolism. Recent data from two independent 2025 studies (Petrovic et al. and Sprenger et al.) demonstrate that intracellular ET binds and activates key sulfur-trafficking enzymes (MPST and CSE), triggering localized hydrogen sulfide (H2S) production. This H2S then persulfidates cytosolic glycerol-3-phosphate dehydrogenase (cGPDH), directly enhancing electron transport chain efficiency and maximizing ATP output. This elevates ET from “defensive scavenger” to “proactive metabolic optimizer” — a mechanistic upgrade with profound implications.
\nIn male mice, ET supplementation at 4–5 mg/kg/day extended median lifespan by 16% and mean lifespan by 21% (Katsube et al., 2024). In Drosophila, lifespan extension was demonstrated across multiple dose ranges.
\nThe honest caveat: human RCT data remains thin. A large cohort study of 3,236 participants over 21 years shows compelling observational links between plasma ET and reduced cardiovascular mortality, but causality is not established. Phase 1 and Phase 2 human trials confirm safety up to 25 mg/day with no adverse signals, but adequately powered, long-term efficacy trials with hard clinical endpoints do not yet exist.
\nThe most immediate practical signal from this review is dietary: eat mushrooms. Oyster, shiitake, and king oyster mushrooms contain 1–7 mg ET per gram dry weight, making them by far the richest accessible source. Regular mushroom consumption is the primary way to counter the age-related decline in blood ET levels.
\nSecond, genetic context matters. If you carry the SLC22A4 L503F (C1672T) variant, standard dietary intake may be insufficient to raise tissue ET to protective levels — and counterintuitively, this variant may increase autoimmune risk in inflammatory contexts. Genetic testing for SLC22A4/SLC22A15 polymorphisms could eventually guide individualized ET protocols.
\nThird, ET operates as an “on-demand” protector: supplementation in healthy, low-stress individuals produces minimal biomarker changes. The benefit signal strengthens under oxidative load — which means individuals with metabolic syndrome, cardiovascular disease, neurodegenerative risk, CKD, or those undergoing hemodialysis (where ET is depleted by 88%) represent the clearest candidates for supplementation trials.
\nPulsed Dose: ET exhibits non-linear pharmacokinetics, high systemic accumulation, active renal reabsorption, and an exceptionally long human half-life of approximately 30 days. Continuous daily high-dose supplementation risks saturating the limited capacity of the OCTN1 transporter and may impede the absorption of essential physiological cations or co-administered drugs like metformin. Intermittent pulse dosing is theoretically superior to avoid transport bottlenecks.
\nMandate Baseline Genetic and Microbiome Screening: Supplemental ET is highly context-dependent and presents an unexpected biological “Achilles’ heel”. Certain anaerobic gut bacteria express ET hydrolases that cleave ET into trimethylamine (TMA), which the liver converts into trimethylamine-N-oxide (TMAO)—a notorious pro-atherogenic metabolite linked to accelerated vascular aging and cardiovascular disease. Individuals must profile their gut microbiome and verify their SLC22A4 genotype (specifically checking for the L503F variant, which dramatically alters baseline transport efficiency) before initiating heavy, unmonitored supplementation protocols.
\nThe current clinically validated dosage range is 5–25 mg/day, with safety confirmed up to 16 weeks in elderly subjects.
\nCanagliflozin (Cana), a common type-2-diabetes drug, is one of the few compounds shown to extend lifespan in mice — but only in males, and only at the standard 180 ppm dose. This study asked a simple question: if females accumulate more of the drug and still get no benefit, would cutting the dose to one-third (60 ppm) protect the female brain by reducing over-exposure? The answer is a qualified “no, but something unexpected happened.” At 60 ppm, the drug improved blood-sugar handling in both sexes but produced no cognitive or motor benefit in either. Yet females — not males — showed reduced age-related inflammation in the hippocampus, the reverse of the male-specific pattern seen at the higher dose. The authors conclude that the sex differences in how Cana acts on the brain are not explained by dose or drug accumulation, but by intrinsic differences in how male and female brains respond.
\nFor years, canagliflozin has been a poster child of geroscience: a widely prescribed diabetes pill that, in the NIA’s rigorous Interventions Testing Program, extended the median lifespan of male mice by 14% — while doing nothing for females. The paradox deepened when researchers discovered that female mice actually accumulate more of the drug in their blood and brains than males. More drug, no benefit. Why?
\nThe prevailing hypothesis was over-exposure: perhaps females were getting too much drug, tipping a helpful intervention into a harmful one (an idea reinforced by a separate finding that starting the full dose late in life actually shortened female lifespan by 6%). If that were true, dialing the dose down should unmask a hidden benefit in females.
\nThis team from Wayne State University, with collaborators at Michigan and UT San Antonio, put that logic to the test. They fed genetically diverse UM-HET3 mice a subclinical 60 ppm dose — one-third of the standard — from 7 months of age, then tracked metabolism, behavior, brain inflammation, and drug levels out to 24 months.
\nThe metabolic story was clean and encouraging: at 18 months, glucose tolerance improved in both sexes, confirming the drug was working peripherally even at a low dose. But the promised cognitive payoff never materialized. Across a full behavioral battery — memory, learning, coordination, anxiety — neither males nor females improved. The robust memory gains previously seen in males at 180 ppm simply vanished at the lower dose, pointing to a dose threshold for brain benefit.
\nThe twist came in the hippocampus. At 60 ppm, female mice showed clear reductions in microglial and astrocyte activation — markers of the “neuroinflammation” that accompanies brain aging. Males showed none. This is the mirror image of the 180 ppm result, where the anti-inflammatory effect was male-only.
\nPharmacology confirmed females still carried 3-to-5-fold higher drug concentrations across brain regions and liver. So neither lowering the dose nor the higher female drug load explains the pattern. The take-home: Cana’s brain effects are governed by sex-specific wiring, not simply how much drug reaches the tissue — a sobering caution for anyone assuming a diabetes drug will protect every brain equally.
\nHonest bottom line for the self-experimenter: Canagliflozin’s brain and lifespan benefits in mice are strongly sex- and dose-dependent, and the effects do not scale intuitively with how much drug you take.
\nQuantified magnitudes worth internalizing:
\nPractical translation: improved glucose tolerance is not a reliable proxy for brain protection. For humans, there is no dosing, sex-adjustment, or timing guidance you can responsibly extract from a mouse study that did not even measure lifespan. The defensible take-home is directional: SGLT2 inhibitors deserve serious study as brain-aging interventions, but their effects are sexually dimorphic, and one-size-fits-all extrapolation is unjustified.
\nMitochondria have long been relegated to the role of the cell’s “powerhouse,” but a comprehensive review by Iñigo San Millán at the University of Colorado (USA), published in the journal Antioxidants (2023), argues they are actually the central negotiators of human health and longevity. The “Big Idea” presented by Iñigo San-Millán is that mitochondrial dysfunction is not merely a symptom of aging but the primary pathogenic driver behind the modern epidemic of non-communicable diseases (NCDs), including Type 2 Diabetes, Alzheimer’s, and various cancers.
\nThe paper shifts the focus from downstream metabolic markers (like blood glucose) to the upstream bioenergetic capacity of the mitochondria. When mitochondria lose the ability to efficiently oxidize substrates—particularly lactate and fatty acids—the resulting metabolic inflexibility triggers a cascade of oxidative stress and systemic inflammation. This “bioenergetic failure” precedes clinical diagnosis by years, suggesting that mitochondrial health is the ultimate biomarker for “biological age”.
\nThe review synthesizes decades of data to show that the metabolic characteristics of elite athletes—marked by high mitochondrial density and “metabolic flexibility”—represent the gold standard for disease prevention. Conversely, the “sedentary phenotype” results in a “clogged” electron transport chain, leading to the accumulation of reactive oxygen species (ROS) that damage cellular DNA and proteins. This bioenergetic collapse is increasingly viewed as the “common denominator” in aging.
\nSource:
\nStudy Design Specifications:
\nMechanistic Deep Dive:
\nNovelty:
\nThe review formalizes the concept that Cardiorespiratory Fitness (CRF) is effectively a proxy for mitochondrial health. It argues for “Metabolic Rehabilitation” through specific Zone 2 exercise protocols to restore mitochondrial function as a primary treatment for chronic disease, rather than just managing symptoms with pharmaceuticals.
\nCritical Limitations:
\nA research team led by Prof. Alessio Lanna (CEO of Sentcell) has released a provocative manuscript describing a new “fluid” organ of the immune system: “Telomere Rivers.” Building on their previous discovery that antigen-presenting cells (APCs) donate telomeres to T cells, this study claims that specific CD4+ T cells subsequently release these telomeres into the bloodstream as extracellular vesicles. These “Rivers” reportedly travel systemically, acting as a “quorum-sensing” youth signal that elongates telomeres in distant tissues (brain, liver, heart) and reverses senescence markers.
\nThe most explosive claim is the lifespan data: 20-month-old mice treated with these telomeric vesicles allegedly survived to a median of ~47 months, with some reaching nearly 5 years (~60 months). If replicated, this would vastly outperform current gold standards like Rapamycin (which typically offers ~15–25% extension). The mechanism hinges on a metabolic switch: the process requires Fatty Acid Oxidation (FAO) and the exclusion of the glycolytic enzyme GAPDH from the vesicles. The authors suggest that “Artificial Rivers”—bioengineered vesicles lacking GAPDH—can replicate this rejuvenation, effectively creating a transplantable “program of youth” that functions independently of the donor’s T cells.
\nSource:
\nRelated reading: New World record lifespan achieved in mice by Rejuvenating T Cells - #2 by EnrQay
\nThis comprehensive review argues that wild blueberries (Vaccinium angustifolium) possess a superior cardiometabolic profile compared to their cultivated counterparts, driven by a phenomenon known as “elicitation.” Unlike cultivated highbush berries grown in optimized conditions, wild blueberries survive in harsh northern climates (Maine, Canada) with poor soil and extreme cold. These environmental stressors force the plants to produce a more diverse and concentrated array of secondary metabolites—specifically anthocyanins—as a survival mechanism.
\nThe review synthesizes evidence suggesting these “stress-hardened” polyphenols offer distinct advantages for vascular aging. While direct antioxidant effects are now considered negligible, the authors present a compelling case for xenohormesis: the idea that consuming stress-adapted plants confers stress resistance to the consumer. The data indicates that wild blueberry consumption acutely improves Flow-Mediated Dilation (FMD) by 1.5%—a clinically significant shift correlated with a 9-17% reduction in cardiovascular disease risk.
\nCrucially, the paper shifts the focus from the berries themselves to their gut-derived metabolites. It posits that the human gut microbiome acts as a “bioreactor,” converting parent anthocyanins (which have low bioavailability of ~1%) into potent phenolic acid metabolites that drive the observed systemic effects. This highlights a critical “Responder vs. Non-Responder” dynamic based on an individual’s microbiome composition, particularly the abundance of Bifidobacteriumand Akkermansia.
\nSource
\nGut Check: Common Postbiotic ‘Butyrate’ Identified as Potent Senomorphic
\nResearchers at the University of Birmingham report that butyrate, a short-chain fatty acid made by fibre-fermenting gut bacteria, can blunt the ageing of human T cells. In older people, both stool and blood butyrate levels fall, and lower levels track with more “senescent” (worn-out but inflammatory) T cells. In the lab, adding butyrate to activated T cells from older donors dialled down their inflammatory secretions (IL-6, IL-8, IL-1beta), reduced DNA-damage and mitochondrial stress markers, and suppressed mTOR/NF-kB signalling. In mice, transferring butyrate-rich stool fluid from young animals cut the build-up of senescent T cells in the spleen. The work positions butyrate as a candidate “senomorphic” — a drug that quiets senescent cells rather than killing them.
\nAs we age, a population of exhausted immune cells accumulates in the body. These “senescent” T cells stop dividing but refuse to die quietly — instead they leak a cocktail of inflammatory molecules that drives the chronic, smouldering inflammation (“inflammaging”) linked to everything from Alzheimer’s to heart failure and rheumatoid arthritis. Clearing or silencing these cells is one of the hottest strategies in longevity medicine.
\nA team led by Niharika Duggal at the University of Birmingham, working with the Quadram Institute, has now pointed the finger at the gut. The big idea: the trillions of microbes in our intestines help keep the immune system young by producing short-chain fatty acids — chiefly butyrate — when they ferment dietary fibre. As the microbiome ages and diversity is lost, butyrate production falls, and the immune system may pay the price.
\nThe researchers first showed the correlation in people. Comparing 40 young (18-37) and 40 older (60+) adults, they found butyrate dropped with age in both stool and, for the first time, in blood serum. Crucially, the less butyrate an older person had in their stool, the more senescent T cells circulated in their blood.
\nTo test causation, they turned to the lab. Taking T cells from older donors and forcing them to divide repeatedly — an accelerated ageing model — they bathed some in butyrate. The treated cells behaved younger: they secreted far less IL-6 and IL-8, carried fewer DNA-damage marks, generated less mitochondrial “rust” (reactive oxygen species), and showed damped activity in the mTOR and NF-kB pathways that orchestrate inflammatory ageing. A gene-expression scan confirmed butyrate switched down a signature panel of senescence and inflammation genes.
\nFinally, in aged mice whose microbiomes had been wiped with antibiotics, a transplant of butyrate-rich fluid from young mouse stool reduced the number of senescent T cells and inflammatory IL-6 in the spleen.
\nThe authors are careful: this is mechanistic and preclinical work, not a clinical trial. But it strengthens the case that a high-fibre diet, prebiotics, or eventually butyrate supplements could become a gentle way to keep the ageing immune system in check. The next step is a proper human trial.
\nThe practical hook is dietary, not pharmaceutical — the paper itself recommends raising butyrate “through dietary, microbial, and therapeutic approaches,” specifically more fibre (fruit, vegetables, legumes, whole grains), prebiotics (inulin, fructooligosaccharides), and butyrate-producing probiotics. Supplement forms floated for future trials are oral sodium butyrate and the precursor tributyrin. No dose, formulation, or human efficacy for anti-ageing has been established, so any action today is a reasonable bet on general gut health, not a proven longevity intervention.
\nEffect-size reality check: the strongest human data point is a correlation — stool butyrate explained about 43% of the variance in senescent CD8 T-cell frequency (R-squared = 0.43, equivalent to r ≈ 0.66, a large association; and R-squared = 0.21, r ≈ 0.46 for a second subset). This is an association, not proof that raising butyrate lowers senescence in you.
\nFor decades, the free radical theory of aging has driven the consumption of generalized antioxidants with mixed, often disappointing, clinical outcomes. A newly published study fundamentally reframes this paradigm by identifying a specific, targetable biological mechanism termed “ferro-aging”. Unlike acute ferroptosis—a rapid, iron-dependent cellular death pathway—ferro-aging is a chronic, low-grade metabolic program that progressively drives cellular senescence and organismal decline. The data demonstrate that iron naturally accumulates across multiple primate organs over time, catalyzing lipid peroxidation. The central executor of this pro-aging shift is acyl-coenzyme A synthetase long-chain family member 4 (ACSL4).
\nIn a high-throughput screen of iron-homeostasis compounds, vitamin C emerged as the most potent suppressor of this aging axis. Crucially, the researchers identified that vitamin C acts not merely as an electron donor, but as a direct structural inhibitor of the ACSL4 enzyme. Target engagement and molecular docking studies confirmed that vitamin C binds directly to the essential catalytic pocket of ACSL4 (residues Thr278, Ser279, and Thr469), mimicking a loss-of-function mutation and halting the thioesterification of polyunsaturated fatty acids.
\nTo validate physiological relevance, the research team conducted a 40-month intervention in aged cynomolgus monkeys. Daily oral supplementation of vitamin C (30 mg/kg, equivalent to approx. 700mg for a human) resulted in a systemic reversal of biological age as measured by multi-omic clocks, encompassing DNA methylation, transcriptomics, and metabolomics. The intervention reversed age-related brain atrophy, restored structural connectivity in the parietal cortex, and improved systemic metabolic markers including triglyceride and insulin levels. This research elevates vitamin C from a generic health supplement to a targeted metabolic modulator of a highly specific lipid-aging mechanism, offering actionable insights for longevity interventions.
\nIn total, the 40-month long oral vitamin C intervention in aged cynomolgus monkeys demonstrated a calculated biological age reversal of three to seven years—representing 10% to 20% of the species’ maximum lifespan—across epigenetic, transcriptomic, and metabolomic clocks, alongside structural brain preservation and metabolic improvements. The most pronounced age-reversal effects were observed in highly metabolic and supportive cell types, such as hippocampal microglia and pancreatic beta cells.
\nSource:
\nYour mouth is slowly drying out, and most people don’t notice until the damage is extensive.
\nThe submandibular gland (SMG)—a walnut-sized secretory organ tucked beneath the jaw—generates roughly two-thirds of your resting saliva. Without adequate saliva, the oral cavity becomes a hostile environment: bacterial populations shift, tooth enamel softens, swallowing becomes difficult, and the mucosal barrier protecting gums and cheeks begins to fray. Xerostomia, the subjective experience of chronic dry mouth, affects an estimated half of adults over 65. Clinicians largely manage it symptomatically. Its underlying biology, particularly why the gland progressively destroys its own secretory tissue with age, has remained underexplored partly because human gland samples are difficult to obtain and because mice—the default lab model—have salivary gland architecture that differs meaningfully from ours.
\nThis paper from UT Health San Antonio proposes a better model and tests one of longevity biology’s most studied drugs within it.
\nThe common marmoset (Callithrix jacchus) is a small South American primate with a compressed lifespan of around 12–15 years and, critically, salivary gland histology that maps closely onto the human pattern: mixed serous and mucous secretory cells arranged in the same lobular architecture, with the same demilune configuration and a ductal system resembling our own. Mice lack these features. The marmoset closes the translational gap.
\nWhat the researchers found when they compared glands from young, middle-aged, old, and rapamycin-treated old marmosets tracks almost exactly what autopsy studies have documented in elderly humans. Old glands had shed roughly a third of their secretory acinar cells, replaced by fibrous connective tissue and lipid-laden stroma. Enzyme markers for matrix remodeling were dysregulated—the balance between tissue-degrading matrix metalloproteinases and their inhibitors was inverted. Ceramide synthase 2, a lipid metabolism enzyme, accumulated. Markers of cellular senescence and programmed cell death were elevated throughout.
\nRapamycin—given orally throughout adulthood at a dose achieving blood levels comparable to some human longevity protocols—substantially reversed this portrait. Glands from rapamycin-treated old animals retained more secretory cells, showed markedly less fibrosis, accumulated less ceramide, harbored fewer senescent and apoptotic cells, and displayed an MMP/TIMP balance resembling the middle-aged group rather than their untreated old counterparts.
\nThe researchers are themselves explicit that this is exploratory and hypothesis-generating. But this is the first primate data connecting rapamycin to salivary gland preservation, and it adds oral health to an already long list of tissues where rapamycin appears to forestall the structural hallmarks of biological aging.
\nFor the aging adult who takes rapamycin for longevity reasons, the practical implication is novel: the intervention may be offering protection against a quality-of-life detriment—dry mouth, oral fragility, dysbiosis—that rarely appears on the target organ list but carries outsized consequences for long-term health.
\nThis paper delivers the first primate-tissue evidence that rapamycin attenuates aging across the full suite of salivary gland hallmarks—acinar loss, fibrosis, matrix remodeling imbalance, lipid dysregulation, apoptosis, and senescence. The marmoset’s histological fidelity to human SMG architecture substantially strengthens translational credibility relative to any rodent dataset.
\nA Gladyshev-lab computational study has built the first aging clock derived from RNA-level damage signatures — not gene expression — showing that transcriptomic deterioration accumulates predictably with age, is partially reversible by rapamycin and caloric restriction, and is measurably accelerated in Alzheimer’s disease blood at a signal strength that conventional expression-based clocks completely miss.
\nAging researchers have argued for decades that molecular damage — not just regulatory drift — is a root cause of biological decline. The evidence base for DNA mutations and protein oxidation is well established. But one entire layer of molecular deterioration has escaped systematic quantification: the damage accumulating in RNA itself.
\nA team at Harvard Medical School and the Broad Institute, led by Vadim Gladyshev, has now built a computational framework that extracts four distinct types of transcriptomic damage from standard RNA sequencing data. These are not soft correlations. The damage types are structurally concrete: premature stop codons generated when introns are wrongly retained in transcripts (producing truncated, non-functional proteins or triggering degradation); alternative splicing errors that physically destroy conserved protein domains; the reactivation of transposable elements — genomic parasites that are normally suppressed — across multiple repeat classes; and gene fusion events, where unrelated RNA strands are incorrectly joined into potentially toxic chimeric molecules. Each of these increases with age. All four damage types positively correlate with chronological age across the majority of human and mouse tissues tested.
\nUsing the GTEx dataset — over 16,000 human tissue samples from 26 tissue types — the team confirmed consistent age-related accumulation across nearly every tissue. The cerebellum carries the highest damage burden of any brain region, consistent with its documented vulnerability to aging-related neurodegeneration. Pancreas, muscle, and blood show the least damage, potentially reflecting higher cell turnover that clears damaged transcriptome-burdened cells before accumulation peaks.
\nFrom these signals, the team trained a machine learning aging clock called tDamAge — first in mice (Pearson r = 0.82) and then in human peripheral blood (test R = 0.827, mean absolute error 9.3 years). The clock responds to interventions in the expected direction across multiple independent datasets: rapamycin, caloric restriction, methionine restriction, and acarbose each reduce tDamAge relative to age-matched controls; SARS-CoV-2 lung infection, BubR1 progeroid mutation, and Klotho heterozygous knockout elevate it.
\nThe most clinically striking finding is in Alzheimer’s disease. When the human blood tDamAge clock was applied to AD patient samples, it detected significantly elevated biological age acceleration compared to cognitively normal controls (p = 0.0099). A standard gene expression clock — built from the same datasets using the same pipeline — failed to detect any significant difference. Transcriptomic damage picks up a signal that expression levels obscure.
\nThe paper also captures a transient rejuvenation window during mouse embryogenesis — a pronounced drop in tDamAge from approximately embryonic day E10/11 through E16 — with the damage clock’s nadir arriving slightly later than expression-based clocks, suggesting damage clearance lags transcriptional reset during development.
\nThe authors frame this within Gladyshev’s deleteriome theory: that aging is defined by the totality of accumulated molecular damage across biological layers. tDamAge provides the first scalable, RNA-layer readout of that entropy. That framing is theoretically sound, though the paper stops short of formal causal proof — a distinction worth keeping in mind.
\nFor the clinician and advanced biohacker, the intervention-response data is the most practically relevant output. Anti-aging interventions already in widespread use — rapamycin, caloric restriction, acarbose, and methionine restriction — each produced measurable reductions in transcriptomic damage age in mice, with fold-change reductions estimated at approximately 5 to 30 percent relative to age-matched controls depending on tissue and age stratum (from Figure 4H). Methionine restriction and dietary restriction showed the most consistent reductions across tissue types; rapamycin’s effects were meaningful but more tissue-specific.
\nConvergence analysis across 22 longevity intervention datasets identified RNA splicing fidelity, chromatin organization, and RNA catabolism as the central shared targets — suggesting these aren’t incidental effects but core mechanistic pathways through which diverse anti-aging strategies operate.
\nThe AD blood signal (approximately 2 to 4 years of tDamAge acceleration relative to controls, estimated from Figure 6F) positions peripheral blood tDamAge as a potential early neurodegeneration marker. At current accuracy (MAE approximately 9.3 years), this clock is unsuitable for individual-level biological age tracking but may have utility as a population-level stratification tool.
\nMining transcriptomes from over 16,000 human and thousands of mouse samples, researchers find that aging corrupts the cell’s RNA-editing machinery in a consistent, damaging way they call “splicing degeneration” — and that this corruption is partially reversed by rapamycin and calorie restriction, positioning it as a candidate new hallmark of aging.
\nEvery human gene is a recipe that can be cooked several ways. Through a process called alternative splicing, a single gene’s instructions are cut and reassembled into multiple distinct protein products — a feat performed on more than nine in ten of our genes. It is one of the great efficiency tricks of biology. This new study argues that, as we age, the kitchen staff get sloppy.
\nResearchers from Vadim Gladyshev’s lab at Harvard Medical School, working with collaborators in Shanghai, scoured a vast archive of gene-activity data: 16,627 human tissue samples from the GTEx project plus large mouse atlases. Rather than simply cataloguing which splicing patterns shift with age — which others have done — they asked a sharper question: do these shifts actually damage the resulting proteins?
\nTheir answer is a fairly emphatic yes. The team built a classifier that flags splicing changes as “damaging” when they introduce a premature stop signal, scramble the protein’s reading frame, or delete a functional protein domain. Aging tissues, they found, are significantly enriched for exactly these destructive events (roughly 2.4-fold over baseline). They distilled this into a single “splicing degeneration” score that climbs steadily with age across most tissues. Intriguingly, the brain appears relatively protected, while the lung and gut are hit hard. Tumours, notably, show the same corrupted signature — hinting at shared machinery between aging and cancer.
\nThe headline-grabbing part: the corruption is not simply the passage of time made visible. When the team examined cells and mice treated with rapamycin — the gold-standard lifespan-extending drug — seven of eight human datasets showed the degeneration score falling. Everolimus (a rapamycin cousin) and calorie restriction pointed the same direction. This suggests splicing fidelity is something the body can, in principle, be coaxed to restore.
\nMechanistically, the authors finger specific “splicing factor” proteins — the regulators that decide how RNA gets cut — as culprits. Silencing many of these factors made cells look transcriptomically older on the lab’s own aging clocks, with the splicing-degeneration regulators producing the largest effect.
\nThe big idea is to promote alternative splicing from a footnote in aging biology to a potential hallmark and therapeutic target in its own right. If splicing fidelity can be measured as a biomarker and nudged back toward youthfulness pharmacologically, it joins a growing list of aging processes that are, at least on paper, addressable. The caveat — and it is a large one — is that this entire edifice rests on correlation and computational inference, not on a single experiment showing that fixing splicing makes an animal live longer.
\nThis is a biomarker-and-mechanism paper, not a trial. The “intervention” data are reanalyses of rapamycin, everolimus, calorie restriction, and metformin datasets that already informed longevity practice — the paper adds a new readout (splicing score), not a new intervention.
\nThe take-home with the most evidential weight is that rapamycin’s benefit signal extends to a previously unmeasured layer of cellular fidelity — reinforcing its standing in a longevity stack. Effect-size reality check: the splicing-degeneration changes are statistically detectable but tiny in absolute terms. Treated-vs-control score shifts in the figures live in the third decimal place (e.g. ~0.235 → ~0.230), i.e. low-single-digit percent relative reductions. The strongest quantitative signal in the whole paper is the baseline enrichment of damaging splicing in old tissue (odds ratio 2.4), not the magnitude of any intervention’s reversal.
\nPractical translation for the stack-builder: nothing changes your protocol today. Rapamycin remains as a key supported lever; metformin and S6K1 deletion gave non-significant trends (p = 0.12 and 0.35). Do not treat “splicing degeneration” as a measurable personal biomarker — there is no assay you can order.
\nIn an interesting new finding for longevity nutrition, a new study from the Universitat Rovira i Virgili in Spain has drawn a hard line between “healthy” fats and “empty” lipids. While olive oil is a cornerstone of the Mediterranean longevity blueprint, this research reveals that not all olive oils are created equal. For the first time, scientists have demonstrated that Virgin Olive Oil (VOO) preserves cognitive function in older adults, whereas Common Olive Oil (COO)—the refined, processed variety often labeled as “Pure” or “Light”—is associated with accelerated cognitive decline.
\nThe mechanism appears to be rooted in a specific gut-brain axis pathway. High-phenolic VOO was found to suppress a specific gut bacterium, Adlercreutzia, which the study identified as a potential driver of cognitive deterioration in this population. Conversely, the consumption of refined olive oil, which lacks the potent polyphenols found in VOO, allowed this bacterium to thrive, correlating with poorer executive function and memory. This suggests that the “health halo” of olive oil depends entirely on its processing grade: the presence of bioactive compounds like hydroxytyrosol and oleuropein is not just a bonus, but the primary engine of neuroprotection.
\nSource:
\nThe study isolates the Gut-Brain Axis as the critical mediator of olive oil’s cognitive effects.
\nThis is one of the first human studies to explicitly decouple the effects of the lipid profile (monounsaturated fats, present in both oils) from the minor polar compounds (polyphenols, present only in VOO). It effectively kills the argument that “olive oil is healthy because of oleic acid” alone—polyphenols are the requisite driver for cognitive preservation.
\nOxford and Nottingham researchers show that low-dose rapamycin protects aging human immune cells by directly reducing DNA damage itself, a mechanism separate from its known effects on metabolism, autophagy, or cell division, and confirm the effect in a small human trial.
\nFor fifteen years, rapamycin has been the closest thing longevity science has to a sure bet: it extends lifespan in every species tested, from yeast to mice, to monkeys. But nobody could fully explain why. The textbook story was indirect: rapamycin dials down the mTOR growth engine, slowing protein manufacturing, quieting cell division, and switching on autophagy, the cell’s recycling system. This new work argues those explanations miss the headline act.
\nThe team, led by Loren Kell with senior scientists Ghada Alsaleh, Lynne Cox, and Katja Simon, went hunting for the source of rapamycin’s power in the immune system, the tissue whose decline arguably drags the rest of the body into old age with it. They deliberately blasted human T cells with zeocin, a chemical that shreds DNA into double-strand breaks, then watched what rapamycin did.
\nThe result was striking. Rapamycin didn’t just clean up damaged cells after the fact; it reduced the actual burden of DNA lesions, measured by the “comet assay,” which physically visualizes broken DNA trailing out of a cell like a tail. Cells given rapamycin carried far less damage, and crucially, they survived. In untreated cultures, the genotoxic hit killed roughly 80 percent of T cells within 24 hours. With rapamycin, around 60 percent were still alive, a threefold survival advantage.
\nThe protection was oddly forgiving of timing. Whether rapamycin was added before, during, or after the DNA-damaging insult, the cells fared better. And the team methodically ruled out the usual suspects: the benefit did not depend on slowing protein synthesis, halting the cell cycle, or boosting autophagy. Something more direct was happening at the level of the genome.
\nThey then profiled immune cells from older people using high-dimensional cytometry, finding that aged immune subsets are enriched for markers of DNA damage, senescence, and mTOR hyperactivity, especially the DNA-damage protein p21. Finally, in a small placebo-controlled human trial, four months of 1 mg/day rapamycin significantly lowered p21 across most immune subsets versus placebo.
\nThe big idea: rapamycin may be a genuine “genoprotector.” If it can shield DNA in a 70-year-old’s immune cells, its potential stretches beyond healthy aging toward cancer radiotherapy recovery and even radiation exposure during spaceflight.
\nThe practical signal here is narrow but real, and it directly concerns anyone already microdosing rapamycin for longevity.
\nDose and exposure. The human arm used 1 mg/day, producing a mean steady-state blood trough of roughly 3.24 nM, within the same order of magnitude as the 10 nM used in cell culture. Critically, at this dose there was no leukocyte suppression, addressing the perennial fear that rapamycin blunts immunity. This supports the “low-dose, non-immunosuppressive” microdosing philosophy rather than weekly high-dose pulsing for this particular endpoint.
\nEffect magnitude. The most quantifiable benefit is cellular survival under genotoxic stress: death fell from ~80% to ~40% at 24 hours, an absolute risk reduction of ~40 percentage points and a relative risk of death of ~0.5 (a 50% reduction). Framed as survival, that is a 3-fold improvement. The DNA-lesion reduction (comet Olive moment) was highly significant (p<0.0001) and appeared within 4 hours, even at the 0-hour timepoint.
\nTake-home. The in-human evidence is limited to a biomarker (p21 reduction), not a clinical outcome. For existing rapamycin users, it strengthens the mechanistic rationale that low-dose rapamycin plausibly defends genome integrity in the immune compartment. It also raises a genuinely novel, testable idea: short-course rapamycin around radiation exposure (medical or occupational).
\nFull paper: https://www.biorxiv.org/content/10.1101/2025.08.15.670559v1
\nRapamycin protects immune cells from DNA damage
\nMechanism: direct genoprotection
\nImmune ageing is linked to DNA damage + mTOR hyperactivation
\nIn vivo human trial (pilot study, NCT05414292)
\nRapamycin acts as a genoprotector, a newly recognized mechanism that may explain its strong anti-ageing effects.
\nPotential applications:
\n![\":white_check_mark:\"](\"https://www.rapamycin.news/images/emoji/twitter/white_check_mark.png?v=12\" "\\":white_check_mark:\\"")
Bottom line:
\nThe study demonstrates for the first time that low-dose rapamycin directly protects human immune cells from DNA damage and reduces senescence in vivo, positioning it as a potential therapy to slow immune ageing and enhance resilience in contexts of DNA damage.
Traditional clinical metrics and standard health assessments have routinely failed to even screen for functional recovery, reinforcing a defeatist dogma that views any aging individual who improves as a statistical anomaly. However, a groundbreaking longitudinal study tracking thousands of older Americans over a 12-year period has shattered this assumption.
\nBy analyzing individual trajectories instead of grouping participants into a single downward average, researchers from Yale University exposed a profound degree of functional plasticity in the aging population. When treated as a homogenous mass, the cohort’s average scores reflected standard decline: cognitive test scores dropped and walking speeds slowed. Yet, beneath this average lay an entirely different reality: 45.15% of participants actually registered distinct improvements in cognitive function, walking speed, or both over the course of the study.
\nThe primary differentiator governing whether an individual fell into the decline or improvement trajectory was not a genetic lottery or a pharmaceutical intervention, but rather their internalized age beliefs. According to Stereotype Embodiment Theory, individuals absorb cultural age stereotypes from youth, which eventually become self-relevant as they cross into older adulthood. Those who maintain a resilient, positive outlook on aging essentially trigger a “snowball effect”. Their constructive mindset reduces systemic stress, promotes health-seeking behaviors, and unlocks deep physiological reserves that drive objective, measurable physical and cognitive optimization.
\nRemarkably, the study also revealed that physical and cognitive aging trajectories are largely decoupled, exhibiting an incredibly low correlation. Improving in a cognitive domain did not automatically dictate improvement in gait speed, and vice versa. This finding challenges the concept of uniform systemic aging and underscores the need for targeted, multi-domain longevity protocols. Ultimately, this research repositions aging not as an unmitigated process of loss, but as a dynamic period capable of stabilization and functional rejuvenation, provided the psychological terrain is optimized.
\nLongevity optimization requires a deliberate psychological retraining protocol alongside metabolic interventions, given that psychological mindsets directly alter long-term physical and cognitive trajectories. Individuals must actively audit and reprogram negative, culturally conditioned age assumptions to prevent the biological assimilation of decline.
\nThe real-world magnitude of this intervention is underscored by its extracted effect sizes:
\nHolding positive age beliefs increases the odds of long-term cognitive improvement by 4% per unit scale increase (OR: 1.04, 95% CI: 1.00–1.08).
\nPhysical function shows an even higher sensitivity, with positive mindsets delivering a 9% increased likelihood of objective walking speed acceleration over a decade (OR: 1.09, 95% CI: 1.02–1.17).
\nFor high-functioning individuals who enter older age with completely normal baseline parameters, the protection is amplified: a positive mindset yields a 14% increased odds of physical improvement (OR: 1.14) and a 17% higher chance of substantial functional optimization when conservative performance thresholds are applied (OR: 1.17, 95% CI: 1.07–1.29). Mindset intervention must be prioritized as a clinical lever on par with standard physical therapeutics.
\nA new study demonstrates that transient mid-life rapamycin treatment in female mice systemically rejuvenates somatic organs and stem cell niches by suppressing hyperactive mTOR signaling. However, the intervention did not salvage fertility or baseline endocrine function once reproductive decline is established, and the somatic benefits rapidly vanish upon drug withdrawal.
\nFor women, the perimenopausal transition represents a period of accelerated physiological decline, marking a sharp increase in susceptibility to age-associated chronic diseases. At the center of this systemic breakdown is the mechanistic target of rapamycin (mTOR) pathway, a master nutrient-sensing hub that drives cellular hypertrophy, translation, and eventual exhaustion when chronically overactivated. While previous research validated that inhibiting mTOR can preserve the ovarian reserve in young or middle-aged mice, a critical question remained: can it reverse damage once the reproductive clock has already run down?
\nTo investigate, researchers targeted 10-month-old female mice. At this life stage, the mice exhibit irregular estrous cycles equivalent to human perimenopause, preceding overt systemic frailty. Initial transcriptomic screens confirmed that both the oocytes and their supporting granulosa cells exhibited hyperactive mTOR signaling, characterized by a major upregulation of ribosome biogenesis and cytoplasmic translation genes.
\nThe team administered a high dose of rapamycin via drinking water for exactly one month. The molecular results across somatic tissues were highly encouraging. Rapamycin successfully suppressed downstream mTOR targets, leading to a sweeping reduction in cellular senescence, fibrosis, and chronic inflammation across the lungs, small intestine, and skeletal muscle. More profoundly, the drug rescued exhausted adult stem cell pools. It replenished quiescent muscle stem cells, increased proliferative intestinal stem cells, and corrected age-related errors in tissue differentiation—such as mitigating the skewed, inflammatory cellular shifts typically seen in the aging gut.
\nHowever, this systemic rejuvenation hit a hard boundary at the germline. Despite clearing out the inflammatory and fibrotic microenvironment of the ovaries, rapamycin failed to restore female fertility or elevate cratered serum estradiol levels. Mating trials yielded no increase in offspring, proving that advanced reproductive aging cannot be engineered backward through late-stage mTOR inhibition.
\nCompounding this limitation, a subsequent one-month drug withdrawal period revealed that the somatic clock immediately wound back up. Once rapamycin was removed, mTOR signaling rebounded, the newly updated stem cell populations plummeted back to aged baselines, and tissue differentiation errors returned. The study reveals an important dichotomy: mid-life mTOR inhibition can powerfully—but transiently—recharge systemic tissue regeneration, but it is entirely powerless against the permanent exhaustion of the female reproductive system.
\nThe Reproductive Timing Window: mTOR inhibition via rapamycin must be initiated well before the onset of advanced reproductive decline if the preservation of fertility or ovarian endocrine architecture is the primary objective. Late-stage interventions fail to rescue oocyte quality or serum estradiol (E2) levels.
\nSomatic Healthspan Rejuvenation: For non-reproductive tissue longevity (lung, gut, skeletal muscle), initiation during the perimenopausal window remains highly effective at clearing senescent cells and reversing stem cell exhaustion.
\nThe Transience of Short-Term Blocks: Biological benefits are highly dependent on sustained pathway inhibition. A 30-day intervention provided clear microenvironmental optimization, but a 30-day washout fully reset tissues to an aged baseline.
\nQuantifiable Real-World Benefits (Effect Sizes): Clinicians and biohackers should note the substantial magnitude of specific tissue improvements during active treatment:
\nFive mechanistically distinct longevity interventions — rapamycin, acarbose, 17α-estradiol, canagliflozin, and caloric restriction — produce partly overlapping metabolic signatures across seven mouse tissues, with the dietary antioxidant ergothioneine rising consistently in brain, plasma, and muscle. A machine-learning model can spot “treated” mice from any of the five interventions even when trained only on the other four.
\nResearchers have long known how to slow aging in mice — calorically restrict them, or give them one of a handful of drugs — but why these very different treatments all work has stayed murky. A team led by Richard Miller’s lab at the University of Michigan, working with the West Coast Metabolomics Center at UC Davis, asked a deceptively simple question: do these interventions, despite hitting different molecular targets, leave a shared chemical mark on the body?
\nTo find out, they treated genetically diverse male mice with one of five validated interventions from young adulthood, then harvested seven tissues — plasma, brain, liver, muscle, kidney, and two fat depots — at one year of age, well before the animals would start dying. They fed the resulting metabolite profiles into XGBoost, a tree-based machine-learning system, and added a useful trick: running each model a thousand times to stop the rankings jumping around with random chance, a recurring headache in this kind of high-dimensional analysis.
\nTwo things stood out. First, the models could reliably tell treated mice from untreated controls in every single tissue. More striking, a model trained on any four interventions could correctly flag mice given the fifth, unseen intervention — implying these distinct treatments share underlying metabolic changes rather than each carving its own separate path.
\nSecond, when the team asked which individual molecules carried the most weight, the answer was mostly tissue-specific. The metabolites that mattered in muscle barely registered in liver, and so on. Only one molecule punched through across multiple tissues: ergothioneine, a fungus-derived antioxidant that mammals cannot make and must absorb from food. It rose in brain and plasma under all five interventions, and in muscle under four. Alongside it, the team saw coordinated reshuffling of fats — a shift toward longer, more flexible polyunsaturated lipids, and in muscle a rise in cardiolipin, a fat critical to mitochondrial function that normally declines with age.
\nThe authors are careful: they don’t yet know whether ergothioneine causes any benefit or is simply a marker of altered nutrient uptake. And they haven’t yet tested whether their model can distinguish genuine longevity drugs from drugs that do nothing for lifespan — the crucial control that would prove this is an aging signature and not just a “something was given” signature. But as a proof of concept, it hints at a faster way to screen candidate anti-aging compounds: read the metabolic tea leaves at one year instead of waiting three for the animals to die.
\nThe single translatable thread is ergothioneine — the only metabolite that rose across multiple tissues under every intervention. It is a dietary compound (richest sources: oyster, king oyster, shiitake mushrooms; lower amounts in tempeh, organ meats, some beans), so unlike the drugs studied, it is something you can actually consume. It is also available widely as a supplement.
\nBut the effect size that matters here is not in this paper. This study shows ergothioneine rising as a correlate of treatments that extend lifespan — it does not show that taking ergothioneine extends lifespan or improves any outcome. The authors explicitly raise the possibility that elevated ergothioneine is a surrogate marker for increased gut absorption of other nutrients, not a causal agent.
\nPractical take-home: ergothioneine is low-risk and biologically plausible, but its benefit remains unproven; treat it as a reasonable dietary hedge, not a validated geroprotector.
\nAging is increasingly viewed not as a passive process of wear and tear, but as an active erosion of the “dark matter” in our genome. Roughly 45 percent of human DNA consists of transposable elements (TEs)—genetic “hitchhikers” like retrotransposons that are normally silenced by epigenetic mechanisms in youth. As we age, this silencing fails, allowing elements like LINE-1 and endogenous retroviruses to reactivate, triggering internal “viral” alarms that drive systemic inflammation and tissue decay.
\nA groundbreaking post-hoc analysis published on the preprint server medRxiv provides the first human evidence that pharmacological intervention can stall this process. Researchers from the University of Colorado Anschutz Medical Center and UC San Diego investigated the effects of two FDA-approved antiretroviral regimens—emtricitabine/tenofovir alafenamide (FTC/TAF, known as Descovy) and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, known as Truvada)—on healthy, non-HIV adults.
\nThe results were formulation-specific and statistically significant. Participants taking FTC/TAF for 12 weeks demonstrated a coordinated reduction across multiple biological aging clocks. Most notably, the PhenoAge clock showed a reduction of 6.33 years (a reduction of 22% from the mean chronological age of the participants), and the DunedinPACE measure—which tracks the current “speed” of aging—slowed significantly. In stark contrast, the FTC/TDF group showed no such improvements, likely due to TDF’s inability to reach high enough concentrations inside the immune cells where retrotransposon activity occurs.
\nBeyond “clocks,” the TAF treatment shifted the immune system toward a more youthful state, increasing the pool of naive CD4+ T cells and reducing inflammatory markers like interleukin-6 (IL-6). By suppressing the reverse transcription of retroelements, TAF appears to lower the cellular “noise” that triggers the chronic inflammation of aging. There were no significant side effects or adverse events reported in this 12 week study in a healthy adults without HIV or chronic comorbidities. While exploratory, this study transforms a decades-old HIV drug class into a frontline candidate for longevity therapeutics.
\nActionable Insights
\nFor those seeking to leverage these findings for healthspan extension, the primary takeaway is the identification of tenofovir alafenamide (TAF) as a potent candidate for “geroprotection”. The study highlights a 12-week window as sufficient to observe measurable shifts in biological age markers, provided the compound achieves high intracellular concentration.
\nThe study’s use of healthy adults aged 18–50 suggests these pathways are active even before the onset of clinical old age. Individuals tracking their biological age via DNA methylation tests (like DunedinPACE) may find this mechanism—retrotransposon inhibition—a high-priority area for future clinical consultation.
\nSource
\nAs we age, our immune systems undergo a double-edged transformation: they become less effective at fighting off new viral threats while simultaneously becoming trapped in a state of chronic, low-grade inflammation—a phenomenon known as “inflammaging.” However, a new clinical trial suggests that a protein found in breastmilk and cow’s milk, lactoferrin, may provide a simple oral intervention to recalibrate this delicate balance in older adults.
\nResearchers at the University of Newcastle (Australia), publishing in the British Journal of Nutrition, conducted a double-blind, randomized controlled trial (RCT) involving 103 healthy adults over the age of 50. For four weeks, participants took either a “low dose” (200 mg), a “high dose” (600 mg), or a placebo. The results revealed a dose-dependent “immuno-tuning” effect that could have significant implications for longevity and pandemic preparedness in an aging population.
\nThe high-dose group showed a notable reduction in systemic inflammatory markers, specifically Interleukin-6 (IL-6) and C-reactive protein (CRP). High levels of these markers are strongly associated with age-related diseases and overall mortality. Perhaps more impressively, when the participants’ immune cells were challenged ex vivo with common respiratory viruses like Rhinovirus (the common cold) and H1N1 (influenza), the cells from those taking high-dose lactoferrin responded more robustly. They produced more anti-viral Interferon-α2 while keeping pro-inflammatory “cytokine storm” signals like IL-6 in check.
\nLactoferrin appears to act as a metabolic rheostat. At the high dose, it boosted the frequency of T cells—the “special forces” of the adaptive immune system that typically decline with age. Meanwhile, the low dose seemed to quiet down overly aggressive innate immune cells like neutrophils and Natural Killer (NK) cells, potentially reducing the collateral damage they cause to healthy tissue.
\nSource:
\nAging skeletal muscle loses the ROS-generating enzyme NOX4, which cripples the NFE2L2 (Nrf2) antioxidant defense system that exercise normally switches on; deleting NOX4 in mice triggers full-blown sarcopenia, frailty, insulin resistance, and even liver disease — all reversible by restoring NOX4 or by giving the broccoli compound sulforaphane.
\nEveryone knows exercise keeps you younger. This paper claims to pin down one of the molecular reasons why — and to show what happens when that mechanism breaks.
\nThe central character is NADPH oxidase 4 (NOX4), an enzyme tucked inside muscle fibers that, paradoxically, produces a “good” reactive oxygen species: hydrogen peroxide. When muscles contract during exercise, NOX4 generates a controlled burst of H2O2. That burst is a signal, not damage. It activates NFE2L2 (also called Nrf2), a master switch that turns on hundreds of protective genes — antioxidant enzymes, mitochondrial-building programs, and protein-clean-up machinery. This is “adaptive homeostasis”: a stressor that makes you more resilient.
\nThe team, led by Tony Tiganis at Monash University in Australia, with collaborators across Europe and the US, first showed in both aged humans and aged mice that NOX4 protein quietly disappears from muscle with age. As it goes, so does the entire NFE2L2 defense network, and oxidative damage to proteins piles up.
\nTo prove cause rather than coincidence, they genetically deleted NOX4 from mouse muscle. The result was striking: these mice didn’t just age — they aged badly. By 20 months they showed overt sarcopenia (muscle wasting), measurable frailty, fat gain, whole-body insulin resistance, systemic inflammation, and — unexpectedly — advanced fatty liver disease that doesn’t normally appear in chow-fed mice.
\nThen comes the hopeful half. The crippled phenotype was rescued three ways. First, exercise training in normal aging mice reinstated NOX4 and the whole defense system — but the same exercise did nothing in NOX4-deficient mice, proving NOX4 is the required relay. Second, re-inserting the Nox4 gene via a virus reversed the damage. Third, and most translationally interesting, sulforaphane — the compound enriched in broccoli sprouts that activates NFE2L2 directly, bypassing the missing NOX4 — corrected nearly everything: muscle mass, strength, blood sugar, inflammation, and liver fat. Notably, it could not reverse established liver fibrosis, a reminder that some damage hardens into permanence.
\nThe Big Idea: the well-known decline of NFE2L2 antioxidant defense in aging may not be an immutable feature of getting old. It may be substantially downstream of physical inactivity, working through NOX4. That reframes a “hallmark of aging” as partly a behavioral consequence — and suggests a pharmacological shortcut for people who cannot exercise.
\nThis is a mechanism paper in mice and cells, not a human trial. But it offers an unusually clean molecular story for why sitting still accelerates decline.
\nThe single most defensible take-home is unchanged but newly mechanized: resistance and endurance exercise is the intervention here. In 12-month-old mice, five weeks of treadmill training (3×/week) restored muscle NOX4 mRNA and protein, plus Nfe2l2, Sod2, and Nqo1 expression, back to or above 6-month-old levels — effectively reversing the molecular signature of inactivity. Effect-size caveat: the paper reports fold-changes and significance, not standardized effect sizes, so the human-translatable magnitude is unquantified.
\nFor those who genuinely cannot exercise, the sulforaphane thread is the actionable pharmacological lead. The dose used in mice (2 mg/kg IP injection) does not translate directly to oral human dosing. The authors lean on a real human anchor (ref 102): a concentrated broccoli-sprout extract taken once daily for 12 weeks lowered HbA1c in type-2 diabetics on metformin. That is the only human efficacy signal in this paper’s orbit, and it is metabolic, not muscular.
\nBottom line: this paper strengthens the “movement is non-negotiable” message and offers sulforaphane as a plausible-but-unproven adjunct. This paper supports sulforaphane as a potential exercise-mimetic for people who can’t (or don’t) exercise (because they are frail or sedentary). The research provides no evidence that sulforaphane helps an already-exercising person preserve muscle.
\nOra Biomedical and the Rapamycin Longevity Lab have launched a project to screen more than 600 mTOR inhibitors in the hope of finding some that are superior to geroscience’s poster child, rapamycin.
\nThe newest Ora’s project is a collaboration with the Rapamycin Longevity Lab led by Krister Kauppi. It entails screening more than 600 mTOR inhibitors to find the ones that work best.
\n\n\n“Currently, rapamycin is considered the gold standard longevity intervention – it works across many animal and even non-animal fungal models,” said Ora CEO Mitchell Lee. “The mechanism of mTOR inhibition has seen extensive development in cancer therapeutics. There’s a broad toolkit of mTOR inhibitors with different patterns of inhibition between mTOR complex 1, mTOR complex 2, and impacts on other kinases. Nobody has comprehensively looked to see if any are better than rapamycin.”
\nThe current project began as a smaller partnership within the Million Molecule Challenge when, in an experiment funded by Kauppi and the Rapamycin Longevity Lab, Ora discovered an mTOR inhibitor that was superior to rapamycin in worms at the same dose. This molecule, called omepalisib, has already been approved by the FDA for treating certain types of cancer, so its way to the clinic as a geroprotector (anti-aging drug) might be relatively short.
\n
Read the full Lifespan.io story here: New Crowdfunding Project Looks for a “Better Rapamycin”
\nLearn more here: RAPAMYCIN LONGEVITY LAB High-efficient lifespan analysis of 601 mTOR inhibitors
\nBe a part of new longevity discoveries by helping out in funding $100 to the largest lifespan analysis of 601 mTOR inhibitors. Thanks to this project we will deliver a big magnitude of unique data to the longevity field. We will also most likely discover mTOR inhibitors that are better than one of the most promising longevity compounds which is Rapamycin. We only need 250 funders who contribute with $100 each to be able to start the first sub project. So let’s together start moving this field forward! You find the link to the fundraising page below. If you can’t contribute financially then one other way is to help out in spreading the word about the project. Every bit of support counts!
\nIt looks like Cambrian Bio has a new product/ spinout that replicates the skin anti-aging benefits of topical rapamycin. This is a vote of confidence for the DIY’ers already using rapamycin skin cream, as we’ve documented: DIY Rapamycin skin cream and Rapamycin May Slow Skin Aging (Drexel U. Study)
\nOf course, rapamycin is off-patent, so they needed to come up with a new molecule they could patent and charge higher prices on. Part of their marketing strategy is to play up “safety” concerns of rapamycin, but topical rapamycin does not enter the bloodstream, and of course the rare significant side effects with orally taken rapamycin are typically at very high, daily doses used in cancer treatment or organ transplant applications vs. the pulsed dosing used in longevity and skincare applications.
\nOverall, I see this launch as a win/win for people. There will be (hopefully) more research done on commercial, topical (patented) rapalogs, and at the same time a low cost option (rapamycin DIY cream) is available for those who are knowledgeable.
\nSee details below:
\n\n\nFor more than a decade, scientists have been looking for ways to safely inhibit mTOR to bring the promise of rapamycin to market.
\nRahul Mehta and Cambrian Bio spinout Rapalogix Health have accomplished the biggest milestone in the mTOR field since 2009. They have successfully brought a novel mTORC1-specific inhibitor to the market.
\nUsing a clinical trial for skin health with leading dermatologists as a jumping off point, Re-Q is now the first product containing an mTORC1-specific inhibitor - RLX-201 - that can be purchased on a shelf (or in this case, through dermatology offices).
\nIf you’ve been following this field, you know how massive this is. It’s a milestone I’ve been striving for for over a decade. The successes we’re already seeing here can help spur the next milestones both in dermatology and the systemic use of mTORC-1 to prevent chronic disease.
\n
\n\nRapalogix Health is proud to announce the launch of https://www.reqhealth.com/ the official home of Re-Q Health, a new advancement in longevity-inspired skincare.
\nPowered by RLX-201, our proprietary longevity-focused molecule, Re-Q was developed from research in cellular health and mTOR-pathway science. The result is a formulation designed to help skin feel balanced, resilient, and refreshed, supporting optimal appearance over time.
\nThis launch marks a milestone in our mission to apply cutting-edge longevity research to the future of skincare.
\n
The mTOR pathway, long recognized as a master regulator of metabolism, cell growth, and repair, is emerging as a central player in the biology of skin aging. Acting as the cell’s signal-integration hub, mTOR helps balance the competing demands of growth and maintenance. When this balance tips toward chronic activation, it can accelerate many of the cellular processes that underlie aging.
\nRecent research highlights that mTOR hyperactivity contributes to multiple hallmarks of aging, including inflammation, senescence, and disrupted tissue homeostasis. Because of this, scientists are increasingly focused on fibroblasts—the skin’s collagen-producing workhorses—as a key point of intervention to restore youthful cellular function.
\nmTOR operates through two distinct complexes, mTORC1 and mTORC2, which play complementary roles in skin physiology.
\nThe emerging consensus among researchers is that selective inhibition of mTORC1—while preserving or enhancing mTORC2 activity—may represent an optimal strategy for maintaining skin vitality. This nuanced approach could suppress the pro-aging effects of mTORC1 hyperactivity without compromising the regenerative benefits governed by mTORC2.
\nThe growing field of “skin longevity” reflects a broader transformation in aesthetic and regenerative medicine: a move away from treating superficial signs of aging toward addressing the molecular causes of tissue decline. With new insights into pathways like mTOR, dermatology is beginning to target cellular senescence, mitochondrial dysfunction, and ECM degradation—the fundamental drivers of visible aging.
\nThe latest findings show that mTORC1 activity increases with fibroblast age, contributing to hallmark aging features such as senescence and disrupted extracellular matrix organization. By intervening at this molecular level, researchers hope to restore not only the appearance but also the function and resilience of aging skin.
\nRelated Research Paper: RLX-201, a Novel mTORC1 Inhibitor With Potential to Promote Skin Longevity and Cellular Health (Dermatologic Surgery)
\n\n\n\n\n","posters":[{"extras":null,"description":"Original Poster","user_id":1,"primary_group_id":null,"flair_group_id":null},{"extras":null,"description":"Frequent Poster","user_id":5358,"primary_group_id":null,"flair_group_id":null},{"extras":"latest","description":"Most Recent Poster","user_id":1612,"primary_group_id":null,"flair_group_id":null}]},{"id":25375,"title":"A Tale of Two Sexes: Rapamycin and Friends Protect Bone in Females, Lifespan in Males","fancy_title":"A Tale of Two Sexes: Rapamycin and Friends Protect Bone in Females, Lifespan in Males","slug":"a-tale-of-two-sexes-rapamycin-and-friends-protect-bone-in-females-lifespan-in-males","posts_count":4,"reply_count":1,"highest_post_number":4,"image_url":"https://www.rapamycin.news/uploads/default/original/3X/b/9/b9fdc094f059e1725356d882de3f410dc142c45e.jpeg","created_at":"2026-06-21T04:31:51.175Z","last_posted_at":"2026-06-22T20:15:58.011Z","bumped":true,"bumped_at":"2026-06-22T20:15:58.011Z","archetype":"regular","unseen":false,"pinned":false,"unpinned":null,"visible":true,"closed":false,"archived":false,"bookmarked":null,"liked":null,"tags":[],"tags_descriptions":{},"views":535,"like_count":7,"has_summary":false,"last_poster_username":"RapAdmin","category_id":5,"pinned_globally":false,"featured_link":null,"news_body":"\nThree of the best-validated lifespan-extending drugs — rapamycin, acarbose, and 17α-estradiol — all preserved spongy (trabecular) bone in aging female mice but did almost nothing in males.
\nOsteoporosis drugs strengthen bone, but they do nothing about the muscle weakness, poor balance, and failing eyesight that actually cause most of the falls that break bones. That is the appeal of “geroprotectors” — drugs that slow aging itself and might fix several of these problems at once. The catch is that almost nobody has carefully checked what these drugs do to the skeleton over the long haul.
\nA team at the University of Sheffield, using mouse cohorts from the US National Institute on Aging’s Interventions Testing Program, did exactly that. They took genetically diverse UM-HET3 mice, treated them for most of their adult lives with rapamycin (an mTOR inhibitor), acarbose (a carb-blocker that flattens blood-sugar spikes), or 17α-estradiol (a “non-feminizing” estrogen), and then imaged their leg bones with micro-CT at 12 and 22 months — roughly mouse middle and old age.
\nThe headline result is a clean dissociation. In females, all three drugs measurably preserved trabecular bone — the lattice-like inner scaffold inside the bone — at 22 months, with rapamycin and 17α-estradiol producing the biggest effects. In males, the effects were essentially nil. That sex split is the surprise, because the lifespan literature points the other way: acarbose and 17α-estradiol extend lifespan mainly or only in male mice.
\nThere is an important nuance under the hood. The drugs did not appear to build new bone. They preserved the number of trabecular struts rather than thickening them, and they did almost nothing to the dense outer cortical shell that carries most mechanical load. That pattern looks like holding the line — slowing the loss of existing architecture, probably by damping inflammation and bone-resorbing osteoclasts — rather than the muscular anabolic rebuild you get from approved drugs like teriparatide.
\nThe practical takeaway is cautious but real: drugs being pursued for healthy longevity may carry a skeletal bonus, at least in females, on top of their other benefits. But the sex-specificity is a warning. You cannot assume a longevity drug helps every tissue, in every sex, the same way. The mechanisms diverge, and the dose, timing, and biological sex all matter.
\nFor a longevity-minded reader, the magnitudes matter more than the headline. In aged (22-month) female mice, relative to same-age controls, the paper reports trabecular bone density increases of roughly +47% with 17α-estradiol, +34% with rapamycin, and +15% with acarbose. In standardized terms these are large statistical effects (posterior probability of a “large” effect size: 92.7% for 17α-estradiol, 85.6% for rapamycin), but note the absolute gains are small (≈1.1–1.5 percentage points of bone volume fraction on a low ~3% baseline). The big-looking percentages come from a low denominator, not a dramatic bone rebuild.
\nHonest take-home messages:
\nA hypothalamic neuropeptide called orexin drives the small, unconscious movements that burn surprising amounts of calories, and this system fades with age, potentially explaining why activity drops and weight creeps up across the lifespan.
\nSome people fidget. They pace on phone calls, jiggle their legs, stand rather than sit, and reorganize the kitchen for no reason. Others sit still. That difference, it turns out, is not just personality, it is neurochemistry, and it may be one of the most underrated levers in metabolic health.
\nThis 2014 review from the University of Minnesota and the Minneapolis VA pulls together a decade of work on orexin (also called hypocretin), a neuropeptide made by a small cluster of neurons in the hypothalamus. Orexin is famous for one thing: when these neurons die, you get narcolepsy. But the same cells do something quieter and arguably more important for longevity. They drive what researchers call spontaneous physical activity, or SPA, and the calories it burns, nonexercise activity thermogenesis, or NEAT.
\nThe big idea is that NEAT is not trivial. The authors cite work showing that lean people spend roughly 150 extra minutes per day on their feet compared to obese people, a difference large enough to matter for body weight over a lifetime. And orexin appears to be the upstream signal that sets this dial. Inject orexin A into the right part of a rat’s hypothalamus and it starts moving more within minutes. Animals with naturally high orexin signaling resist becoming obese even when fed a high-fat diet, without eating less.
\nHere is the longevity hook. Orexin signaling does not stay constant. It rises through development, peaks in adulthood, and then declines with age. As orexin drops, so does spontaneous movement, and so does the body’s ability to defend a healthy weight and a stable circadian rhythm. The same decline is loosely linked to the cognitive and sleep problems that accumulate in old age, and to the dramatic orexin neuron loss seen in Parkinson’s and Alzheimer’s brains at autopsy.
\nThe provocative implication, which the authors are careful to frame as a future direction rather than a finished result, is that age-related weight gain, daytime sleepiness, and reduced activity might share a common upstream cause: a quietly failing orexin system. If true, drugs that selectively boost orexin tone could one day target the “I just don’t feel like moving” problem directly, rather than relying on will power to exercise.
\nThe honest answer is that this paper offers no validated human intervention yet. While new drugs are in phase 3 clinical trials and one is scheduled to be released by the end of 2026, there is currently no orexin pill you can take. But two extractable, real-world signals are worth stating with their effect sizes.
\nFirst, the NEAT effect is large in absolute terms. The cited human data show lean individuals accumulate about 150 extra minutes of daily movement and sit roughly 2 hours less than obese individuals, translating to an estimated additional 5 kcal/kg/day of energy expenditure. For an 80 kg person that is roughly 400 kcal/day, on the order of a daily training session, achieved entirely through posture and ambulation rather than structured exercise. The take-home: standing, pacing, and low-intensity movement are not metabolically trivial, and deliberately increasing them is the closest current proxy for “boosting orexin-driven activity.”
\nSecond, the directionality matters for behavior. In animals, high baseline activity precedes and protects against weight gain rather than merely following from leanness. This supports front-loading movement habits before metabolic decline sets in rather than after.
\nSource:
\nDecades before a single memory slips, the same midlife problems that clog arteries — high blood pressure, high apoB/LDL, diabetes, belly fat, atrial fibrillation — are quietly seeding dementia, and this review argues that aggressive, timed cardiovascular prevention is one of the most powerful brain-protection strategies we have.
\nFor most of medical history, the heart and the brain were treated as separate kingdoms with separate specialists. A new perspective from a US preventive-neurology group argues that this division is a clinical mistake we can no longer afford. Their core claim is simple and increasingly hard to dispute: cardiovascular disease and neurodegenerative disease are largely the same disease process, viewed through two different organs.
\nThe evidence for overlap is striking. Up to 75% of people with a clinical Alzheimer’s diagnosis also carry vascular pathology in the brain, and cerebral small-vessel disease shows up in as many as 80% of Alzheimer’s cases at autopsy. The shared culprits — hypertension, dyslipidemia, type 2 diabetes, obesity, atrial fibrillation and the APOE ε4 gene — don’t just travel together; they act on the same machinery, throttling blood flow, breaking down the blood-brain barrier, igniting chronic inflammation, and impairing the brain’s ability to clear toxic amyloid and tau.
\nThe numbers that make this actionable are the modifiable ones. The authors cite estimates that 22% to 44% of dementia risk by age 80 is attributable to modifiable cardiovascular factors, and that up to 45% of dementia cases worldwide could be prevented by addressing 14 known risk factors. Against a lifetime dementia risk now estimated at 42%, that is an enormous lever.
\nThe “Big Idea” is not merely that prevention works — it is that timing is everything. Earlier is better. Midlife is the vulnerable window: high blood pressure, high cholesterol and diabetes in your 40s and 50s do durable structural damage. Yet the same review warns that in late life the script flips. Blood pressure that is too low (under 90/60), or overly tight glucose control can result in hypoglycemia risks, producing a U-shaped curve where both extremes can harm the aging brain.
\nThe authors push toward precision prevention: replacing one-size-fits-all targets with individualized risk scoring (CAIDE, CogDrisk), genomics (APOE), and an emerging panel of blood biomarkers — p-tau217, p-tau181, GFAP, neurofilament light — that promise to track brain aging the way a lipid panel tracks heart risk. They also single out apoB as a more honest measure of atherogenic risk than LDL-C alone.
\nThe take-home is a paradigm shift rather than a pill: treat the vascular system early and intelligently, and you may be running the single best dementia-prevention program currently available.
\nThe practical message: protect your vasculature in midlife and you measurably protect your brain. Magnitudes the paper supports:
\nCaveat: most numbers are associations from observational data, so real-world personal benefit is plausibly smaller.
\nScientists have long suspected that aging, at its molecular core, follows a conserved script — that a mouse dying of old age and a human doing the same are, in some fundamental sense, running the same program. A landmark study published in Nature now provides the most comprehensive evidence yet that this is true, and offers a toolkit to read and score that program in real time from a blood sample or tissue biopsy.
\nResearchers at Harvard Medical School’s Brigham and Women’s Hospital, led by Vadim Gladyshev and Alexander Tyshkovskiy, assembled more than 11,000 gene expression profiles spanning 25-plus tissues from four mammals — mouse, rat, crab-eating macaque, and human — and used them to train a suite of transcriptomic clocks. Unlike DNA methylation clocks (which read chemical marks on DNA), these new “tAge” clocks read which genes are being switched on or off, and at what level, to predict not just how old an organism is, but how close to death it is — right now.
\nThe mortality clock is the centerpiece. Trained on expected all-cause hazard rates derived from Gompertz survival models, it distinguishes animals running on borrowed time from those aging slowly, predicts time-to-death in the Framingham Heart Study (n = 3,698 people) with accuracy comparable to second-generation DNA methylation clocks like DunedinPACE, and does so with fully interpretable gene-level readouts.
\nThe team then dissected the architecture of biological aging into 28 co-regulated gene modules — distinct cellular subsystems each with its own aging “clock” — revealing that different interventions target different parts of the machinery. Caloric restriction primarily reverses metabolic ageing (mitochondrial, lipid, and haem metabolism modules), while inflammatory stress (LPS, chronic disease) predominantly drives immune-module aging. Crucially, heterochronic parabiosis — sharing young blood with old mice — produced a systemic tAge reduction spanning most modules, suggesting its rejuvenating effects are genuinely multi-pathway rather than pathway-specific.
\nThree genes emerged as the most consistent molecular markers of mortality across every species, tissue, and disease model tested: CDKN1A (encoding p21, a cell-cycle brake and senescence enforcer), LGALS3 (galectin-3, a pro-inflammatory lectin), and GPNMB (an inflammation-associated glycoprotein). All three predict all-cause mortality and a wide spectrum of chronic diseases in over 50,000 UK Biobank participants at the protein level — bridging the gene-expression findings to clinical reality.
\nPerhaps most striking is the embryogenesis finding: a genuine molecular “ground zero” occurs around embryonic day 10 in mice, during which the transcriptomic mortality signature resets to its lowest recorded level, with CDKN1A and LGALS3 among the key genes suppressed. Early embryogenesis, caloric restriction, and heterochronic parabiosis all share this suppressive signature — suggesting the biology of rejuvenation may converge on the same molecular levers, regardless of how it is triggered.
\nFor individuals and clinicians:
\nThe most immediately actionable finding is the identification of three plasma proteins — GPNMB, CDKN1A/p21, and LGALS3 — as validated mortality and multimorbidity predictors in over 50,000 people. Effect sizes from UK Biobank Cox models (adjusted for age and sex) show standardized hazard ratios of approximately 1.1 to 1.6 per standard deviation of circulating protein level for all-cause mortality. This means that for each meaningful step up in the blood level of these proteins, your risk of dying from any cause increases by 10% to 60%. For comparison, many commonly used clinical risk markers (like LDL cholesterol for heart disease) have hazard ratios in a similar range. The fact that these proteins predict all-cause mortality — not just one disease — is what makes them particularly notable. Of the three proteins, galectin-3 (LGALS3) is the broadest predictor — it’s not just tied to one organ or one disease, but to six major disease categories spanning the heart, liver, kidneys, and metabolic system. This makes biological sense: galectin-3 drives fibrosis (progressive scarring) and chronic inflammation, which are underlying mechanisms in all of those conditions. A protein that contributes to organ damage across multiple systems naturally shows up as a predictor of multiple diseases.
\nPathway-level intervention targeting:
\nCaloric restriction’s mortality benefit operates primarily through metabolic modules (mitochondrial, lipid, haem/ROS pathways), not inflammatory ones. Conversely, chronic inflammatory load — from any source — drives the immune/interferon mortality modules hardest. This provides a rational basis for combining a metabolic intervention (caloric restriction, rapamycin, canagliflozin) with an anti-inflammatory one (e.g. PectaSol-C) to address distinct aging subsystems simultaneously rather than overlapping mechanisms.
\nSenescence as the common currency: CDKN1A/p21 upregulation is the single most consistent pro-mortality signal across disease, damage, and ageing. Senolytic or CDKN1A-targeting strategies therefore address a genuine pan-tissue ageing driver. [Confidence: Medium — protein correlation, not yet causal proof in humans]
\nIn a newly published clinical trial from the University of Reading in the United Kingdom, in collaboration with Kasetsart University in Thailand, researchers have identified a potent, cost-effective tool for the longevity toolkit: black rice. While the longevity community often fixates on high-cost berry extracts and isolated supplements, this study demonstrates that substituting a standard staple—brown rice—with anthocyanin-rich black rice can induce measurable improvements in verbal memory and systemic inflammation within just eight days.
\nThe “Big Idea” here is the marriage of metabolic stability with neuroprotection. The study utilized a randomized, single-blind, crossover design involving 24 older adults. Unlike previous research focusing on acute “spikes” in performance, this trial tracked both the 2-hour postprandial window and an 8-day short-term period. While acute consumption merely attenuated the typical post-meal cognitive dip associated with high-carbohydrate loads, the 8-day protocol yielded significant gains in final and total word recall, alongside a 12% reduction in serum Interleukin-6 (IL-6)—a key driver of “inflammaging”.
\nSource:
\nThe findings suggest the primary driver is the Anti-Inflammatory Pathway , specifically the reduction of IL-6.
\nThis is the first study to demonstrate the acute and short-term effects of anthocyanin-rich black rice on cognitive performance, inflammation, and microvascular function in older adults. It bridges the gap between animal models and human clinical outcomes using a culturally relevant, affordable staple food rather than an expensive extract.
\nThe mention of this 2008 study in the recent David Sinclair podcast here got my interest… so here is more information and a link to the full paper:
\nThe long-held medical dogma that extreme old age inevitably culminates in advanced neurodegeneration and vascular decay has been fundamentally challenged by a single brain. A landmark case study profiles a 115-year-old Dutch woman who remained cognitively vibrant until her death, performing above the average of healthy adults aged 60 to 75 on standardized neuropsychological evaluations. This performance is highly anomalous in supercentenarian populations, where cognitive decline is typically severe and widespread. The patient, who proactively donated her body to science at age 82, was tracked longitudinally by researchers who discovered that her extraordinary longevity did not come at the cost of neurological integrity.
\nUpon her death from metastatic stomach cancer, an immediate post-mortem examination was executed to capture pristine cellular data. The gross and histopathological findings were stunning: her vascular system was completely free of significant atherosclerotic changes, a condition virtually unheard of in centenarians. In the brain, the typical hallmarks of senility and Alzheimer’s disease were practically absent. Neuropathologists found zero beta-amyloid plaques and no vascular pathology. Hyperphosphorylated tau protein—a driver of neurofibrillary tangles—was strictly confined to a minimal Braak-stage 2 distribution, meaning it remained clinically silent and isolated from the temporal isocortex.
\nMost remarkably, quantification of her locus coeruleus—a brainstem nucleus highly vulnerable to age-related cell death—revealed a neuron count equivalent to that of a healthy individual decades younger. The preservation of these critical catecholaminergic neurons strongly correlates with her retained executive function and memory. This case report provides empirical proof that human cognitive capacity can extend far beyond current average lifespans without triggering mandatory brain disease. It shifts the focus of longevity science from accepting cognitive decline as an immutable law of chronologic time to targeting the specific, preventable pathologies that drive neurodegeneration.
\nThis case study serves as an existential proof-of-concept for longevity medicine: archetypal brain aging can be entirely decoupled from neurodegenerative disease. While the subject possessed an undeniable genetic advantage—her mother survived to age 100—the primary actionable takeaway lies in her absolute preservation of vascular health. The absolute avoidance of systemic atherosclerosis directly prevented the micro-infarcts and ischemic white matter changes that typically catalyze cognitive decline in the elderly.
\nExtracting the real-world magnitude of this benefit reveals a massive cellular effect size: the subject retained between 16,390 and 16,736 locus coeruleus neurons at age 115. When contrasted against existing literature cited in the study for typical 103-to-104-year-olds—who average a mere 9,500 neurons—this represents an approximate 75% increase in neuron retention over her chronologically matched peers. Her cellular baseline was effectively preserved to match healthy adults under 60 to 82 years old.
\nTo replicate this phenotype, biohackers must aggressively target endothelial health and proteostatic clearance. Actionable protocols include optimizing lipid fractions (ApoB/Triglycerides), maintaining low systemic inflammatory markers (hs-CRP), and maximizing glymphatic clearance via high-quality deep sleep to prevent the early-stage accumulation of tau and amyloid aggregates. [Confidence: Medium]
\n